The risk of non-steroidal anti-inflammatory drug-induced heart failure in people with chronic kidney disease: a systematic review

Bethany S. Ward, Michael Naughton, Dorothea Nitsch, Mariam Molokhia

Abstract

Aim To examine the risk of non-steroidal anti-inflammatory drug-induced heart failure in patients with chronic kidney disease.

Methods Embase, Medline, CENTRAL, Web of Science, and Google Scholar were searched for papers published in English between 1st January 1999 and 31st May 2020. Papers were included if some participants had chronic kidney disease, were exposed to non-steroidal anti-inflammatory drugs, and where heart failure was measured as an outcome. Papers were assessed for risk of bias using the Cochrane Risk of Bias 2 tool for randomised controlled trials, and ROBINS-I for observational studies.

Results A total of 2480 independent papers were retrieved. Following abstract screening, 165 full texts were reviewed to identify seven eligible papers: two randomised controlled trials, four cohort studies, and one case-control study. For chronic kidney disease (stage 3–5), relative risk for heart failure ranged from 0.3 to 1.9 with 95% confidence interval 0.04 to 15.1. Results were not pooled due to study heterogeneity. We attributed bias to heterogenous populations studied, probable confounding due to partially adjusted risk estimates, and heterogenous measurement of the heart failure outcome.

Conclusion Overall, there are only a few studies to refute or support an increased risk of heart failure associated with taking non-steroidal anti-inflammatory drugs in patients with chronic kidney disease, and therefore no robust evidence was available.

Keywords Anti-inflammatory agents, non-steroidal · Cyclooxygenase 2 inhibitors · Kidney failure, chronic · Heart failure

Introduction

Background & rationale

Chronic kidney disease (CKD) has a global prevalence of ~11% (including albuminuria), and this figure rises with age (Hill et al. 2016). In England, the lifetime lost health-related quality of life is estimated as £7.18 billion for CKD stages 3–5 (Nguyen et al. 2018).

Chronic pain may be present in up to 60% of individuals with CKD (Wu et al. 2015). Older individuals with CKD are more likely to need treatment for pain due to musculoskeletal conditions (Zhang and Rothenbacher 2008). In the UK, the prevalence of chronic pain is estimated to be 44%, increasing to 62% in people over 75 years old (Fayaz et al. 2016). Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen are widely prescribed to help with joint symptoms of inflammation and pain (Wu et al. 2015); general practice surgeries in England issued 841,738 NSAID prescriptions in January 2021 alone, and 10,219,360 prescriptions throughout 2020 (EBM Data Lab University of Oxford 2020). This may be changing in the future, as a recent NICE guideline on chronic pain has recommended against the use of NSAIDs in chronic primary pain (National Institute for Health and Care Excellence 2021). A systematic review found NSAID use up to 21% in individuals with CKD in Western countries, although use declined with increasing CKD stage (Lefebvre et al. 2019). In general population studies, NSAIDs have been associated with cardiovascular harm, but the evidence for the degree of risk associated with different NSAIDs is poor. NSAIDs are known to cause renal impairment, acute kidney injury, gastrointestinal bleeding, thrombotic events, myocardial infarction, and heart failure (HF) in the general population.
population, which are common complications in CKD. NSAID use is cautioned in people with existing HF or CKD, as CKD itself is associated with an increased risk of developing HF (Zhang et al. 2017).

Much of the evidence of drug harms comes from observational real-world data. Most interventional studies are designed for efficacy, and therefore not powered to investigate harms by level of estimated glomerular filtration rate (eGFR). The literature does not provide robust evidence for the safety of NSAIDs in CKD, as very few studies have exclusively studied individuals with CKD.

A September 2019 search of the Cochrane Central Register of Controlled Trials (CENTRAL) and protocol registry PROSPERO retrieved no systematic reviews looking at the risk of NSAID associated HF in people with CKD, and so a gap in the literature was identified. Therefore, this systematic review was carried out to assess the risk of HF to people with CKD who are exposed to NSAIDs, to inform prescribing choices in CKD.

**Objectives**

Our study aim was to assess the risk of HF to a CKD stage 3–5 population of taking NSAIDs. The participants were identified as adults with CKD stage 3–5, i.e., eGFR < 60 ml min⁻¹ 1.73 m⁻². The intervention studied included any single NSAID or combination use and included cyclooxygenase 2 inhibitors (coxibs) and acetylsalicylic acid (aspirin) as well as traditional NSAIDs. Comparison groups could include non-NSAID exposure, placebo, or no treatment. We studied new diagnosis of HF as an outcome.

**Methods**

This systematic review has been registered with PROSPERO and can be found with the ID CRD42020192605. Authors have reported according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria (Moher et al. 2009); the checklist is available as supplementary material. Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) was used to evaluate quality of evidence (Siemieniuk and Guyatt 2021).

**Search strategy**

Databases searched included Embase and Medline (via OVID), CENTRAL, Web of Science, Google Scholar, PROSPERO, and Trial registries (International Standard Randomised Controlled Trials Number (ISRCTN), and clinicaltrials.gov), and related conference proceedings and abstracts. The search strategy (see supplementary material): search items used MeSH terms for NSAIDs, kidney disease, and heart failure. For filtering types of study, British Medical Journal Best Practice study design search filters were used to include only randomised controlled trials (RCTs) and observational studies (BMJ 2020). The search was filtered to include studies published between the 1st of January 1999 and the 31st of May 2020.

**Study selection**

This review included: (i) randomised controlled trials and observational studies (case-control, case-series, and cohort studies), (ii) in English language, (iii) considering NSAID-exposed participants compared to non-NSAID exposure, no treatment, or placebo, (iv) with CKD ≥ stage 3, i.e., GFR < 60 ml min⁻¹ 1.73 m⁻², and (v) HF as the outcome. HF was diagnosed by New York Heart Association (NYHA) or International Classification of Disease (ICD) criteria or reduced left ventricular ejection fraction (LVEF ≤ 50%). Exclusion criteria were (i) participants < 18 years old, pregnant, or breastfeeding, (ii) case reports, and (iii) pharmacokinetic, pharmacogenetic, or animal studies.

Two authors (BW & MM) screened titles and abstracts identified by the searches. Any disagreements were resolved by consensus discussion; a third reviewer was available (DN) but further adjudication was not required. Relevant full-text papers were retrieved and independently screened by two authors (BW & MM), and any disagreements resolved by consensus. The reasons for exclusion after full-text review were documented [Fig. 1].

**Data extraction**

Search results were imported to Endnote for review. Previously specified outcome data was identified in published studies and extracted separately.

Data extracted included: author, publication date, location, study design, population/sampling method, participant inclusion criteria, participant exclusion criteria, NSAID studied, exposure definition, CKD stage/eGFR, unexposed group, sample size, % male/female, outcome, outcome measure, number of cases, confounders adjusted for, reported outcome statistic, outcome as relative risk (with 95% confidence interval), and funding source.

**Quality assessment**

Risk of bias assessment was performed on all included studies. RCTs were assessed using the Cochrane Risk of Bias 2 (RoB2) tool (Sterne et al. 2019), and observational studies using ROBINS-I (Sterne et al. 2016). Studies were classified as high, medium, or low risk of bias. Further detail is given in the supplementary material.

A funnel plot was constructed to analyse publication bias within this review using STATA 16.
Data synthesis and analysis

Individual study relative risks (RR) were investigated by study type (RCT, cohort, and case–control) and displayed in a forest plot including RR with 95% confidence interval (CI) for the appropriate studies [Fig. 2]. For representation in a forest plot, all studies were assigned a RR and 95% CI figure. We used reported adjusted RR from the paper, but those reporting an alternative statistical measure such as hazard ratio (HR) or no measure reported, had a RR and 95% CI calculated based on the original study data."

STATA 16 software was used for the forest plots, including I² measure for heterogeneity. Random effects models were used to allow for heterogeneity.

Three of the studies looked at solely dialysis patients (CKD stage 5); a subgroup meta-analysis was considered but not deemed appropriate, and risks were reported separately for all studies which included those with moderate to severe CKD (stage 3–4). The GRADE framework was applied to inform recommendations based on the findings of this review.

Results

Study selection

A detailed description of study selection is shown in Fig. 1. Overall, 1676 independent papers were retrieved from Embase and Medline and a further 804 from CENTRAL, Web of Science, Google Scholar, and trial registries (clinicaltrials.gov, and ISRCTN); 2480 independent papers in total. Of these, 2315 papers were excluded by screening the abstracts and titles, removing duplicates and ineligible results based on criteria defined in the protocol. The remaining 165 papers were screened using the full text, leaving seven papers eligible for inclusion.

Cochrane CENTRAL and PROSPERO as well as the database search found no systematic reviews relevant to NSAID-associated HF risks in the CKD population, excluding one which did not find any eligible studies (Marks et al. 2011) and a study which considered the cardioprotective effect of aspirin in CKD with no focus on heart failure or alternative NSAIDs (Qu et al. 2020).
Study characteristics

Table 1 summarises a description of study characteristics. Studies selected comprised of two RCTs, and five observational studies, consisting of four cohort and one case-control study. Because of the high number of characteristics, it was considered helpful to split them into three separate, vertically-placed groups, each covering different aspects of the seven studies: studies 5 to 7 involved dialysis.

HF risks in CKD stages 3 & 4

García Rodríguez et al. reported the highest RR for HF, in a mixed population of hypertensive, diabetic, and CKD participants (defined as individuals with ‘renal failure’ recorded on their general practice records encompassing individuals with CKD), and included several different NSAIDs (García Rodríguez and Hernández-Díaz 2003). The population limits any conclusions which might be drawn relating to CKD, because individuals with hypertension and diabetes (without CKD) were also included and were at high risk of HF. The Kim et al. cohort study shows an increased risk of all cardiovascular events for CKD patients not using dialysis (eGFR < 60 ml min\(^{-1}\) 1.73 m\(^{-2}\)) when prescribed aspirin, although no specific risk for HF was estimated (Kim et al. 2014).

The two randomised controlled trials examining NSAID use in CKD stages 3 or 4 do not suggest increased risks of taking NSAIDs (aspirin/celecoxib) on the development of HF or cardiac events (Goicoechea et al. 2018; Sinsakul et al. 2007). However, numbers are small and a composite outcome was used which may allow cardioprotective effects to counteract the HF risk. Sinsakul et al. included an exclusively diabetic population with CKD (diabetic nephropathy with proteinuria > 500 mg d\(^{-1}\) or serum creatinine ≤ 265.2 μmol L\(^{-1}\)), thus limiting generalisability (Sinsakul et al. 2007). A composite outcome was used, ‘cardiac event/congestive heart failure’, so HF cannot be specifically identified. The small sample size (24 participants) means the group may not be representative of the wider population, and this increases the likelihood of chance or outliers affecting the result, demonstrated in the wide 95% CI of 0.07–15.08. The Goicoechea et al. study was a highly selective trial of patients with eGFR 15–60 ml min\(^{-1}\) 1.73 m\(^{-2}\) which excluded participants with co-morbidities, exposed participants to low-dose aspirin, as indicated for primary prevention of cardiovascular disease, and also studied a small sample of 111 participants (Goicoechea et al. 2018). The low dose may be the reason for the reported protective effect of aspirin in this study, but the lack of serious comorbidities may also be a contributing factor.
| Study | Location | Study Design (Year) | Population/ Sampling | Inclusion Criteria | Exclusion Criteria |
|-------|----------|---------------------|----------------------|--------------------|-------------------|
| 1. Goicoechea et al. (2018) | Spain | RCT: intervention, open label (2010-2015) | CKD patients- Community of Madrid Centres | eGFR 15–60 ml min⁻¹ 1.73 m² without previous cardiovascular events. Males 45–79 years or females 55–79 years | Previous cardiovascular or vascular disease: arrhythmia, arrest, angina, acute MI, stroke, >50% carotid stenosis, documented peripheral vascular arteriopathy. Hospitalisation in the three months prior to inclusion. Acetyl-salicylic acid allergy, Coagulopathy. Thrombocytopenia <150,000 platelets. Liver Disease by hepatitis B or C, or HIV. Immunosuppressive treatment <12 weeks before inclusion |
| 2. Sinsakul et al. (2007) | USA | RCT: placebo-controlled, double blinded, crossover (2003-2004) | Diabetic nephropathy patients from North American institutions | Diabetes Mellitus type 1 or 2 and diabetic nephropathy with proteinuria >500 mg d⁻¹ or serum creatinine ≥265.2 μmolL⁻¹ | Patients with other renal diseases, recent history of acute renal failure, hyperkalaemia ≥5.1 mmolL⁻¹ at screening, any recent myocardial event, or history of peptic ulcer disease or gastrointestinal bleeding |
| 3. García Rodríguez and Hernández-Díaz (2003) | UK | Case-Control (1996) | CKD recorded on patient GP records | 40-84 years old. Enrolled with GP > 2 years. Hypertension, diabetes, or renal failure in history. | Pregnant, or previous diagnosis of heart failure or cancer |
| 4. Kim et al. (2014) | South Korea | Retrospective cohort study (1990-2013) | CKD patients at Gachon University Gil Medical Center | CKD eGFR < 60 ml min⁻¹ 1.73 m²<18 years old, records lacking information on serum creatinine levels, and patients who received dialysis prior to entry in the study | |
| Dialysis | | | | | |
| 5. Lai et al. (2017) | Taiwan | Cohort (1997-2008) | End stage renal disease on haemodialysis >3 months, with atrial fibrillation and high thromboembolic risk | >3 months on haemodialysis for ESRD; diagnosis of atrial fibrillation, and CHA2DS2-VASc score ≥2 | Cancer, renal transplant, peritoneal dialysis |
| 6. Liu et al. (2016) | China | Cohort (2008-2014) | Haemodialysis patients in HD Center of Shanghai No. 1 People’s Hospital | 18-80 y old, who were undergoing regular haemodialysis for more than 3 months | Active malignancies, haemorrhagic diatheses, liver diseases, platelet counts <100,000/ml, or noncompliant with medical therapy |
| 7. Trespalacios et al. (2003) | USA | Cohort (1996) | US Renal Data System Dialysis Morbidity and Mortality Wave 2 database (dialysis) | 1st date ESRD in 1996, survived dialysis (incl. peritoneal) for 90 days | No pre-existing Congestive Heart Failure |
| Study | Location | NSAID studied | Exposure Criteria | Study Design (Year) | Population/ Sampling | Inclusion Criteria | Exclusion Criteria | Sample Size | % Female | Outcome |
|-------|----------|---------------|-------------------|---------------------|----------------------|-------------------|-------------------|-------------|---------|---------|
| 1     |          | Aspirin       | Aspirin 100mg daily |                     | CKD stage/ GFR       | CKD patients on standard care - not given aspirin | 111 in total, 50 aspirin, 61 non-aspirin | 50%          | 32.4% overall, 36% aspirin, 29.5% non-aspirin | Congestive heart failure |
| 2     |          | Celecoxib     | Celecoxib 200mg daily for 6 weeks |                     | Placebo              | 24                | Not Reported       |             |         | Cardiac event/ congestive heart failure |
| 3     |          | NSAIIDs: aceclofenac, acemetacin, diclofenac, etodolac, fenbufen, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, mafenamic acid and tiaprofenic acid. | Prescription within last month |                     | 'renal failure' listed on GP record | Non-users of NSAIIDs | 2278 (46 with renal failure) | 48% in whole study. Subgroup not reported. |         | Heart Failure |
| 4     |          | Aspirin       | Aspirin 100mg daily |                     | Stage eGFR < 60 ml min⁻¹ 1.73 m⁻² | Non-user of aspirin | 2751 in total, 1380 aspirin, 1371 non-aspirin | 41.3% in aspirin, 51.8% in non-aspirin |         | Cardiovascular disease |
|       |          |               |                   |                     |                      |                   |                   |             |         |         |
|       |          |               |                   |                     |                      |                   |                   |             |         |         |
|       |          |               |                   |                     |                      |                   |                   |             |         |         |
|       |          |               |                   |                     |                      |                   |                   |             |         |         |
| Dialysis |          |               |                   |                     |                      |                   |                   |             |         |         |
| 5     |          | Aspirin       | Not Reported       |                     | 5 / End Stage Renal Disease ICD9 code 585 which states GFR <15 ml min⁻¹ 1.73 m⁻² | Not taking aspirin | 951 in total, 814 aspirin and 137 none | 62% overall, 60% in aspirin, 75% non-aspirin |         | Congestive Heart Failure |
| 6     |          | Aspirin       | Aspirin prescription in records - 100mg daily |                     | Diagnosis of one of: Hypertensive renal injury, Diabetic kidney disease, Chronic glomerulonephritis, Biopsy-proven IgAN, Polycystic kidney disease, Gout kidney, Obstructive nephropathy, Lupus nephritis, Chronic interstitial nephritis, Postrenal transplantation | No aspirin prescription | 406 in total, 152 aspirin, 254 non-aspirin | 53%        |         | Congestive Heart Failure |
| 7     |          | Aspirin       | Not Reported       |                     | End stage renal disease patients so assumed Stage 5 | Not taking aspirin | 436                  | Not Reported | Hospitalisation for Congestive Heart Failure |

**Study 1:** NSAIDs: aceclofenac, acemetacin, diclofenac, etodolac, fenbufen, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, mafenamic acid and tiaprofenic acid.

**Study 2:** NSAIDs: celecoxib, etoricoxib, ibuprofen, indomethacin, ketoprofen, mafenamic acid and tiaprofenic acid.

**Study 3:** NSAIDs: aspirin, celecoxib, diclofenac, etodolac, indomethacin, ketoprofen, mafenamic acid and tiaprofenic acid.

**Study 4:** NSAIDs: aspirin, celecoxib, diclofenac, etodolac, indomethacin, ketoprofen, mafenamic acid and tiaprofenic acid.

**Study 5:** NSAIDs: aspirin, celecoxib, diclofenac, etodolac, indomethacin, ketoprofen, mafenamic acid and tiaprofenic acid.

**Study 6:** NSAIDs: aspirin, celecoxib, diclofenac, etodolac, indomethacin, ketoprofen, mafenamic acid and tiaprofenic acid.

**Study 7:** NSAIDs: aspirin, celecoxib, diclofenac, etodolac, indomethacin, ketoprofen, mafenamic acid and tiaprofenic acid.

**Study Outcome Measure:** Number of Cases

**Study Confounders Adjusted for:**

**Study Reported statistic:** RR (95% CI)

**Study Comments:**

**Study Funding:**
| Study | Location | Study Design (Year) | Population/ Sampling | Inclusion Criteria | Exclusion Criteria | Support/Funding |
|-------|----------|---------------------|----------------------|-------------------|--------------------|-----------------|
| 1     | Congestive heart failure= LVEF <40% and congestive symptoms classified by the New York Heart Association as II to IV | 5/50 in ASA, 17/61 in standard. | Assumed not adjusted | HR 0.40 (0.15–1.08) | 0.31 (0.04-2.64) | May include dialysis; composite outcome | Sociedad Española de Nefrología (SEN) and Sociedad Madrileña de Nefrología (SOMANE). MG, GFJ, DA, AO, and JL are supported by ISCIII RETIC REDINREN RD016/009 and FEDER funds. |
| 2     | Not Reported | 1 in each group | Treatment, baseline protein excretion, study site, period, systolic blood pressure, weight, and interaction between treatment and period | None | 1.00 (0.07-15,.08) | May include dialysis; all diabetic; composite outcome | Support from National Institutes of Health and Pfizer |
| 3     | GP reported dyspnoea, with pulmonary oedema; peripheral oedema and raised jugular venous pressure on examination; or evidence of heart disease \ angina pectoris, myocardial infarction, other ischemic heart disease, atrial fibrillation, heart failure, or cerebrovascular disease on electronic records | 1780 | Age, sex, BMI, smoking, alcohol use, comomedication and comorbidity | RR 1.9 (1.3-2.8) | 1.9 (1.3-2.8) | May include dialysis; not all participants CKD | Research grant from AstraZeneca (pharmacological company) |
| 4     | angina pectoris, myocardial infarction, other ischemic heart disease, atrial fibrillation, heart failure, or cerebrovascular disease on electronic records | 490 in aspirin, 279 in non-aspirin | age, gender, comorbidities, proteinuria, baseline eGFR, baseline bloods, and medications. | HR 2.106 (1.82-2.44) | 1.74 (1.54-1.98) | No dialysis, some participants with previous cardiovascu- lar disease. | Chong Kun Dang Pharmaceutical Corp. in Korea |
| **Dialysis** | | | | | | |
| 5     | ICD-9 codes: 398.91, 402.X1, 404.X1, 404.X3, 422, 425, or 428 | 341 in aspirin, 39 in no treatment | Age, sex, diabetes mellitus, hypertension, and hyperlipidaemia | HR 1.28 (0.91-1.81) | 1.47 (1.11-1.94) | Haemodialysis only | Grant from Tzu Chi General Hospital |
| 6     | New York Heart Failure Classification | 60 cases of CHF diagnosis, 24 aspirin/36 non-aspirin | Mortality figures adjusted for age, sex, Hb, albumin, type 2 diabetes, cancer, and ultrafiltration per week | RR 1.11 (0.69–1.79) | 1.11 (0.69–1.79) | Haemodialysis; mixed renal problems | Grants from Shanghai medical key subject construction project, Key Discipline Construction Project of Pudong Health Bureau of Shanghai, Outstanding Leaders Training Programme of the Pudong Health Bureau of Shanghai, and Fudan University Advantages of Disciplines Building |
| 7     | Hospitalised in Medicare and CHF from ICD9 code 428.x | 27 | Age, sex, diabetes, previous coronary heart disease, and haematocrit | HR:1.59 (1.01-2.50) | 1.61 (1.07-2.43) | All dialysis; hospitalised with CHF | United States of America Government |
We were unable to estimate pooled risks for stages 3 and 4 of CKD, as studies found were based on small numbers of individuals with CKD and included composite outcomes or populations, deemed not suitable for inclusion in a meta-analysis. Figure 2 shows a forest plot to summarise the results of each study as RR and 95% CI.

**HF risks in renal dialysis CKD (stage 5)**

This review could suggest participants undergoing dialysis (stage 5 CKD) have increased risk of HF when prescribed aspirin. If analysed assuming suitable homogeneity, the combined RR for the studies containing participants on dialysis is 1.43 (95% CI 1.16–1.76). However the dialysis participants in two of the studies had significant underlying CVD (Lai et al. 2017; Trespalacios et al. 2003), although lower in Liu et al. (2016), suggesting these results are likely to be confounded by underlying CVD.

**Risk of bias within studies**

We undertook a GRADE assessment (Siemieniuk and Guyatt 2021) to examine bias in the meta-analysis results, which can be found in full in the supplementary material. We found no firm evidence to suggest an increased risk of aspirin-associated HF in dialysis patients (CKD stage 5), due to probable confounding by indication (i.e., patients were likely to be prescribed aspirin for underlying IHD, which is a known risk for HF).

Both RCTs were found to be of medium risk of bias overall using the Cochrane RoB2 tool (Table 2). All four observational studies received medium risk of bias judgements using the ROBINS-I tool (Table 3).

Further detail on the risk of bias assessment can be found in the supplementary material.

The supplementary material also contains a funnel plot aiming to indicate the risk of publication bias. The small number of studies makes it difficult to draw conclusions, but the plot is largely symmetrical around the mean effect size, and standard error is small in several of the studies.

**Table 2.** Cochrane Risk of Bias 2 tool (Sterne et al. 2019) for randomised controlled trials

| Study (Cochrane Risk of Bias 2 tool) | Randomisation | Assignment | Adherence | Missing outcome data | Measurement of the outcome | Selection of reported results | Overall |
|-------------------------------------|---------------|------------|-----------|----------------------|---------------------------|-----------------------------|---------|
| Goicoechea et al. (2018)            | medium        | medium     | medium    | low                  | medium                    | medium                       | medium  |
| Sinsakul et al. (2007)              | low           | medium     | low       | low                  | medium                    | high                         | medium  |

**Discussion**

**Summary**

We were unable to estimate NSAID-induced HF risks separately for CKD stages 3, 4, or 5 due to insufficient data.

Lai et al. demonstrated the risk of congestive HF to a CKD stage 5 haemodialysis population with high thromboembolic risk and atrial fibrillation when prescribed aspirin. The study focused on a subset of participants with atrial fibrillation, who are known to have increased risks of HF, probably due to underlying ischaemic heart disease.

Liu et al. studied a haemodialysis population with heterogeneous kidney disease including hypertensive renal injury, diabetic kidney disease, polycystic kidney disease, lupus nephritis, and chronic interstitial nephritis. Although the participants had a lower prevalence of cardiovascular disease co-morbidity (9.2%) than the other studies included, this may still cause biased results due to increased risks of HF.

Trespalacios et al. (2003) undertook a retrospective cohort study using the US Renal Data System Dialysis Morbidity and Mortality Wave 2 database for chronic dialysis patients (both haemodialysis and peritoneal) to assess their risk of hospitalisation for HF. Trespalacios et al. (2003) noted a large proportion of pre-existing cardiovascular disease (30.2% in HF hospitalisation cases and 23.4% in those not hospitalised for HF) and prevalent hypertension. Around a quarter of participants were African American, and the use of only ‘Medicare’ participants limits the study to a largely older population. All these factors are likely to affect results through selection bias and confounding.

**Comparison with existing literature**

This review considered HF risk to CKD patients partially due to the established evidence for NSAID-associated HF in the general population. A meta-analysis of over 700 randomised trials in the general population, which included people with CKD, discovered that all the NSAIDs studied led to a doubled risk of HF diagnosis or admissions (Coxib and traditional NSAID Trialists’ (CNT) Collaboration 2013). Most of the
studies included in this review studied aspirin, which may confer lower risks of HF than other NSAIDs.

A Cochrane systematic review intended to review RCT evidence of safety of NSAIDs (amongst other pain medications) in a population with rheumatoid arthritis and comorbid renal conditions (Marks et al. 2011). No studies were found eligible for inclusion in this review, highlighting the lack of trials looking at NSAID safety in individuals with CKD, with or without comorbidities. However, a recent systematic review found that aspirin had no cardioprotective effects in the CKD population, with no significant reduction in stroke, MI, heart failure, or cardiovascular disease (Qu et al. 2020). Qu et al. included data from three studies (Kim et al. 2014; Lai et al. 2017; and Goicoechea et al. 2018) found eligible for this review (Qu et al. 2020).

Well-designed randomised trials are needed to clarify the risk of HF when prescribing NSAIDs to the CKD population. A randomised controlled trial, ‘ATTACK’ (aspirin to target arterial events in chronic kidney disease), is currently investigating low-dose aspirin in CKD for prevention of major vascular events; results are awaited and will contribute to the evidence base (National Institute for Health Research 2018).

Iwagami et al. (2018) showed that HF and acute kidney injury were the top cause-specific hospital admission outcomes in those with CKD stages 3–5 compared to age- and sex-matched controls (Iwagami et al. 2018). HF prevalence increases with age from around 1% in a general population aged 55–64 to 17.4% in those aged ≥ 85 (Levy et al. 2002).

Previous studies, based in the United States, have estimated that individuals with CKD have a 3-fold increased risk of incident HF (Kottgen et al. 2007).

NSAIDs provide an analgesic and anti-inflammatory effect but have also been used for cardiovascular protection; aspirin is prescribed in low doses to people with high risk of a thrombotic event such as a stroke or myocardial infarction (García Rodríguez and Hernández-Díaz 2003). NSAIDs, including aspirin, are best used when benefits to reduction of cardiovascular disease are balanced against risk of bleeding, so it is important to assess risks of HF in dialysis patients when deciding on medications. Additionally, it is difficult to produce research comparing NSAIDs to no treatment due to ethical concerns regarding pain treatment.

**Strengths & limitations**

This is a comprehensive systematic review on an important clinical problem. The search of literature was thorough, and relevant papers have been discussed. This review has not attempted to run an inappropriate meta-analysis using a small group of heterogenous studies, and instead highlights the necessity for a stronger and more CKD-focused evidence base.

Unfortunately, there are several possible sources of bias within the sources reviewed, including study population, confounding by indication through underlying CHD, NSAID exposure, and HF classification.

The García Rodríguez et al. (2003) high RR was not attributable to CKD participants alone, as they were analysed as one population with hypertensive and diabetic patients, with 2% of the group categorised as having ‘renal failure’, a term previously used to describe CKD but also established renal failure requiring dialysis. García Rodríguez et al. reported on NSAID safety in a diverse, high-risk population, but do not provide sufficient evidence to study effects in an exclusively CKD population. Heterogenous populations were included, with varying definitions of CKD.

There is possible misclassification of exposure to NSAIDs due to over-the-counter use. We were unable to ascertain participant adherence to NSAID prescriptions and the correct doses were assumed, which could underestimate the true risk. Incomplete adjusting for other comorbidities and confounders, including deprivation, may cause further bias in estimates.
Kim et al. (2014) used cardiovascular events as an endpoint, and reported no separate figures of HF incidence. A possible reason for the differences in the studies on general CKD is that a variety of NSAIDs were considered the exposure. Arfè et al. (2016) demonstrated significant differences between NSAIDs in relation to risk of hospitalisation for HF, reporting celecoxib odds ratio (OR) = 0.96 (95% CI 0.90–1.02) whereas ibuprofen OR = 1.24 (95% CI 1.07–1.43) and ketorolac was found to have OR = 1.85 (95% CI 1.62–2.12). It would be important to know the risk associated with each NSAID for people with CKD, as it is likely that risk also varies between NSAIDs in the CKD population.

Finally, it is possible that some of these results may have been due to chance.

**Conclusion**

**Key findings**

There is no firm evidence for NSAID-induced HF in CKD, and consequently more work is needed. We were unable to estimate HF risk in CKD separately for stages 3, 4, or 5.

**Implications for research and practice**

The clinical relevance of this review is focussed in the dialysis studies, looking at the most severely affected patients (CKD stage 5) but does not suggest HF may be attributable to aspirin, due to confounding through underlying CHD. The evidence for CKD stages 3 and 4 is inconclusive, as studies were small and prone to bias. Well-conducted larger studies are required to determine risk of HF associated with NSAIDs in CKD Stage 3 and 4 and inform future guidelines and practice. If NSAIDs are used in CKD populations, risks for HF, bleeding, acute kidney injury, and other adverse effects should be carefully monitored and mitigated against (Zhang et al. 2017). A balanced risk–benefit analysis can help inform clinicians and patients to enable the best decisions for care.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s10389-021-01654-3.

**Authors’ contribution** This systematic review’s conception and design, literature search, and analysis were performed by Mariam Molokhia and Bethany Ward. The first draft of the manuscript was written by Bethany Ward, and all authors made significant contributions to previous versions of the manuscript. All authors read and approved the final manuscript.

**Funding** This work is supported by the National Institute for Health Research Biomedical Research Centre at Guy’s and St Thomas’ National Health Service Foundation Trust and King’s College London.

**Availability of data and material** The data underlying this article will be shared on reasonable request to the corresponding author.

**Code availability** Not applicable.

**Declarations**

**Conflict of interest** No conflict of interest to declare.

**Ethics approval** Not applicable.

**Consent to participate** Not applicable.

**Consent for publication** Not applicable.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

Arfè A, Scotti L, Varas-Lorenzo C et al (2016) Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ 354:i4857. https://doi.org/10.1136/bmj.i4857

BMJ (2020) Study design search filters. https://bestpractice.bmj.com/info/us/toolkit/learn-ebm/study-design-search-filters. Accessed 19 October 2019

Coxib and traditional NSAID Trialists’ (CNT) Collaboration (2013) Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382(9894):769–779. https://doi.org/10.1016/S0140-6736(13)60900-9

EBM Data Lab University of Oxford (2020) Non-steroidal anti-inflammatory drugs. https://openprescribing.net/bnf/100101. Accessed 12 January 2020

Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT (2016) Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. BMJ Open 6:e010364. https://doi.org/10.1136/bmjopen-2015-010364

García Rodríguez LA, Hernández-Díaz S (2003) Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure. Epidemiology 14(2):240–246. https://doi.org/10.1097/01.EDE.0000034633.74133.c3

Goicoechea M, de Vinuesa G, Quiroga B et al (2018) Aspirin for the primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: a multicentre randomised clinical trial (AASER study). Cardiovasc Drugs Ther 32:255–263. https://doi.org/10.1007/s10557-018-6802-1

Hill NR, Fatoba S, Oke J et al (2016) Global prevalence of chronic kidney disease- a systematic review and meta-analysis. PLoS One 11(7): e0158765. https://doi.org/10.1371/journal.pone.0158765

Iwagami M, Caplin B, Smeeth L, Tomlinson LA, Nitsch D (2018) Chronic kidney disease and cause-specific hospitalisation: a matched cohort study using primary and secondary care patient data.
Kim AJ, Lim HJ, Ro H et al (2014) Low-dose aspirin for prevention of cardiovascular disease in patients with chronic kidney disease. PLoS One 9(8):e104179. https://doi.org/10.1371/journal.pone.0104179

Kottgen A, Russell SD, Loehr LR et al (2007) Reduced kidney function as a risk factor for incident heart failure: the Atherosclerosis Risk in Communities (ARIC) study. J Am Soc Nephrol 18(4):1307–1315. https://doi.org/10.1681/ASN.2006101159

Lai Y-H et al (2017) Hazards of antithrombotic therapy on hemodialysis patients with atrial fibrillation and high thromboembolic risk: a Taiwanese population-based cohort study. Int J Clin Exp Med 10(9):13982–13991

Lefebvre C, Hindié J, Zappitelli M, Platt RW, Filion KB (2019) Non-steroidal anti-inflammatory drugs in chronic kidney disease: a systematic review of prescription practices and use in primary care. Clin Kidney J 13(1):63–71. https://doi.org/10.1093/ckj/szf054

Levy D, Kenchaiah S, Larson MG et al (2002) Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347(18):1397–1402. https://doi.org/10.1056/NEJMoa020265

Liu J, Pan Y, Chen L et al (2016) Low-dose aspirin for prevention of cardiovascular disease in patients on haemodialysis: a 5-y prospective cohort study. Haemodial Int 20(4):548–557. https://doi.org/10.1111/hdi.12409

Marks, J. L, Colebatch A, Buchbinder R, Edwards C (2011) Pain management for rheumatoid arthritis and cardiovascular or renal comorbidity. Cochrane Database Syst Rev (10):CD008952. http://doi.wiley.com/10.1002/14651858.CD008952.pub2

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. https://doi.org/10.1136/bmj.b2535

National Institute for Health and Care Excellence (2021) Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain. NICE, London. https://www.nice.org.uk/guidance/ng193. Accessed 24 April 2021

National Institute for Health Research (2018) An aspirin a day for chronic kidney disease. NIHR, Leeds, UK. https://www.nihr.ac.uk/blog/an-aspirin-a-day-for-chronic-kidney-disease/1104. Accessed 21 April 2021

Nguyen N, Cockwell P, Maxwell AP et al (2018) Chronic kidney disease, health-related quality of life and their associated economic burden among a nationally representative sample of community dwelling adults in England. PLoS One 13(11):e0207960. https://doi.org/10.1371/journal.pone.0207960

Qu B, He Y, Wu L et al (2020) Is there a cardiovascular protective effect of aspirin in chronic kidney disease patients? A systematic review and meta-analysis. Int Urol Nephrol 52(2):315–324. https://doi.org/10.1007/s11255-019-02350-8

Siemieniuk R, Guyatt G (2021) What is GRADE? BMJ publishing group limited 2021. https://bestpractice.bmj.com/info/toolkit/learn-ebm/what-is-grade. Accessed 13 May 2020

Sinsakul M, Sika M, Rodby R et al (2007) A randomised trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease. Am J Kidney Dis 50(6):946–951. https://doi.org/10.1053/j.ajkd.2007.09.005

Sterne JAC, Savović J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https://doi.org/10.1136/bmj.l4898

Sterne JAC, Hernán MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https://doi.org/10.1136/bmj.i4919

Trespalacios FC, Taylor AJ, Agodoa LY, Bakris GL, Abbott KC et al (2003) Heart failure as a cause for hospitalisation in chronic dialysis patients. Am J Kidney Dis 41(6):1267–1277. https://doi.org/10.1016/s0272-6386(03)00359-7

Wu J, Ginsberg JS, Zhan M et al (2015) Chronic pain and analgesic use in CKD: implications for patient safety. Clin J Am Soc Nephrol 10(3):435–442. https://doi.org/10.2215/CJN.06520714

Zhang Q-L, Rothenbacher D (2008) Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 8:117. https://doi.org/10.1186/1471-2458-8-117

Zhang X, Donnan PT, Bell S et al (2017) Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol 18:256. https://doi.org/10.1186/s12882-017-0673-8

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.